Please login to the form below

Not currently logged in

Pfizer closes on Xeljanz filing in ulcerative colitis

Latest positive data could help the slow-growing drug meet blockbuster sales expectations

Pfizer's XeljanzNew phase III results for Pfizer's Xeljanz in ulcerative colitis (UC) put the company on course to file for approval in a disease that affects millions of people worldwide.

Xeljanz (tofacitinib) is already approved to treat rheumatoid arthritis (RA) but has failed to grow as quickly as hoped in that setting, so the US pharma giant is hoping new indications will help the product meet its blockbuster sales expectations.

Once tipped as a $3bn drug, Xeljanz has been compromised since its launch in 2012 by the FDA's decision to approve only a 5mg twice-daily dose in RA and ask for more evidence on the safety of a higher 10mg dose.

Safety concerns also prevented approval for RA in Europe, and Pfizer hit another major setback last November after the FDA turned down Xeljanz as a psoriasis therapy - though action for the chronic plaque psoriasis supplemental New Drug Application was laid out in October.

The latest data from the OCTAVE Sustain trial backs the use of the drug as a maintenance therapy for patients with ulcerative colitis - a debilitating inflammatory bowel disease that can cause abdominal pain, fever, weight loss and chronic, bloody diarrhoea.

Previously, Pfizer reported two positive phase III trials of Xeljanz - OCTAVE Induction 1 and 2 - which showed that the drug was able to bring patients with moderate-to-severe active UC into remission more effectively than placebo.

OCTAVE Sustain compared the 5mg and 10mg doses of Xeljanz to placebo in patients already in remission from UC, and showed that both doses were able to reduce the risk of relapse significantly. Detailed results from the study will be presented at a future medical conference, said Pfizer.

The company is also conducting a long-term, open-label extension study of patients enrolled in its three main phase III trials and will also include data from this trial in marketing applications, currently scheduled for the first half of 2017.

Xeljanz has started to gain momentum, with sales up 66% to $172m last year, but will need a major boost from new indications if it is to push above the $1bn sales threshold.

In addition to UC, the FDA approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets for the once-daily treatment of moderate to severe RA in patients who have had an inadequate response or intolerance to methotrexate in February.

Article by
Phil Taylor

29th July 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...